Pharmacogenetics

Chair

Erika Cecchin
Aviano, Italy

Vice-Chair

Fabienne Thomas
Toulouse, France

Committee Purpose

  • To promote education and training on the clinical application of pharmacogenetics to personalize drug therapy and to foster the exchange of knowledge in the field.
  • To facilitate and harmonize the translation of pharmacogenetic testing into the clinical practice in different world areas.
  • To encourage discussions on the clinical relevance of specific pharmacogenetics tests, to encourage research into clinically important areas with respect to drug treatment.
  • To encourage interaction between pharmacologists and toxicologists to promote “toxicogenetics”.
  • To promote a vision of an integrated model of personalized medicine taking advantage of available knowledge on patients’ genetics, pharmacological interactions and therapeutic drug monitoring.

2025

  • Contributed one Episode to IATDMCT Podcast ‘Eight Drugs A Week’ – ‘Pharmacogenetics: Here, There and Everywhere’ with Erika Cecchin & Jesse Swen (Episode 13).
  • Involvement of IATDMCT PGx Committee in new CPIC guidelines for anti-microbial agents.
  • The new Vice Chair – Fabienne Thomas – for the Committee has been identified and unanimously approved by the Committee members for the 2025-2027 term.
  • Five new members have joined the Committee during 2025 -Currently 26 members representing 13 countries in 4 continents.

    • 2024

  • Active participation in (inter)national conferences and many peer reviewed papers and guidelines.

    • 2021

  • Make proposal for IATDMCT PGx session in the next Congress.
  • Propose/validate a (minimal) NGS panel to be used for pharmacogenetic applications in the field of TDM and CT (to be published in IATDMCT Compass).
  • Explore the need for updated PGx guidelines in immunosuppressive therapy.
  • Increase membership.

    • 2019

  • Informed members of IATDMCT on current discussions regarding PGx testing, on new potentially interesting pharmacogenetic markers, and the emergence of new technologies.
  • Organization of 2 PGx sessions in Foz do Iguaçu 2019
  • Morning session PGx on Tamoxifen (23/09/2019), Dr J. Swen and Dr Y. Tanigawara
  • Symposium on PGx in oncology (25/09/2019) DPYD and 5-FU, Dr T. van Gelder; UGT1A1 and beyond, Dr J.C. Boyer; ABCG2 and TKIs Dr T. Terada.

    • 2025

    IATDMCT 2025 in Singapore

  • One Symposium by the PGx Committee – “Prospective implementation of pharmacogenomics in the clinical practice: NGS versus targeted genotyping strategies” – Speakers: Rachel Conyers, Yusuke Tanigawara, Andrew Somogyi, Jae-Gook Shin.
  • One Joint Symposium by the PGx & TDM in Oncology Committees – “Towards integration of Pharmacogenetics and Therapeutic Drug Monitoring (TDM) in Clinical Practice of oncology patients” – Speakers: Balram Chowbay, Nuala Helsby, Carlo Largiader, Stephen Ackland

    • 2024

    IATDMCT 2024 in Banff

  • One Symposium by the PGx Committee – “Genetic diversity in clinical pharmacogenomics: challenges and opportunities for NGS”; Speakers: Daniel Hertz, Daniel Mueller, Rachel Tyndale

    • 2021

    Haufroid V, Picard N. Pharmacogenetics Biomarkers Predictive of Drug Pharmacodynamics as an Additional Tool to Therapeutic Drug Monitoring. Ther Drug Monit. 2019 Apr;41(2):121-130. doi: 10.1097/FTD.0000000000000591. PMID: 30883506.

    2019

    Brunet M, van Gelder T, Åsberg A, Haufroid V, Hesselink DA, Langman L, Lemaitre F, Marquet P, Seger C, Shipkova M, Vinks A, Wallemacq P, Wieland E, Woillard JB, Barten MJ, Budde K, Colom H, Dieterlen MT, Elens L, Johnson-Davis KL, Kunicki PK, MacPhee I, Masuda S, Mathew BS, Millán O, Mizuno T, Moes DAR, Monchaud C, Noceti O, Pawinski T, Picard N, van Schaik R, Sommerer C, Vethe NT, de Winter B, Christians U, Bergan S. Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report. Ther Drug Monit. 2019 Jun;41(3):261-307. doi: 10.1097/FTD.0000000000000640. PMID: 31045868.

    • ‘Pharmacogenetics and gender medicine: a key synergy for personalized therapies’ by Eleonora Cecchin, S Gagno, B Posocco, JJ Swen, E Cecchin
    • ‘Closing the ethnicity gap in pharmacogenomics: insights from tacrolimus pharmacokinetics and the impact of CYP3A5*6’ by A Levens, DJ Moes, JJ Swen, together with Immunosuppressive Drugs Committee
    • Haufroid V and Picard N on behalf of the Pharmacogenetics Committee. Genotyping versus Phenotyping: The case of fluoropyrimidines. IATDMCT Compass June 2019: 9-10.
    • Picard N and Haufroid V on behalf of the Pharmacogenetics Committee. Physician and pharmacist awareness and education about pharmacogenetics: The next challenge for clinical implementation? IATDMCT Compass December 2018: 9-10.
  • Established interaction with IUPHAR Pharmacogenomics Drug Metabolism and Transport working group (Chair- Andrew Somogyi) to plan joint educational webinars

    • Erika Cecchin (Chair)
    Fabienne Thomas (Vice-Chair)
    Pierre Bet
    Eleonora Cecchin
    Rachel Conyers
    Jessica Cusato
    Maarten Deenen
    Laure Elens
    Lei Fu
    Lana Ganoci
    Chris Hamamoto
    Vincent Haufroid
    Amar Levens
    Mark Linder
    Iain A M MacPhee
    Vangelis Manolopoulos
    Jan Gerard Maring
    Espen Molden
    Smita Pattanaik
    Nicolas Picard
    Bianca Posocco
    Livija Šimičević
    Andrew Somogyi
    Jesse Swen
    Yusuke Tanigawara
    Ron Van Schaik
    Steven Wong

    Powered by  GDPR Cookie Compliance
    Privacy Overview

    This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.